Buchanan Ingersoll & Rooney Adds Counsel Genevieve M. Spires to its New Jersey FDA and Pharmaceuticals Section Practice
“Buchanan Ingersoll & Rooney is expanding its FDA practice in New Jersey, which is complemented by the firm’s Washington, D.C.-based FDA practice,” explained Spires. “The firm’s depth in life sciences and FDA compliance, the ability to practice with former FDA and CMS attorneys, and the firm’s national platform made this an attractive move for me,” she added.
Spires provides counsel on the laws and industry standards applicable to the sale and marketing of pharmaceuticals and medical devices. She joins Buchanan’s prominent FDA practice, which includes members from offices in Newark, Princeton, New York and Washington, D.C. Shareholder Linda Pissot Reig, who joined the firm in February of 2011, heads up the practice locally.
About Spires
In addition to counseling clients on FDA regulatory issues, Spires has experience defending pharmaceutical, medical device, industrial and consumer product manufacturers in product liability suits, including mass torts, federal multi-district litigation, class actions and individual state and federal suits in New Jersey, New York and other jurisdictions.
Spires received her J.D. degree from Rutgers University School of Law-Newark, where she was editor-in-chief of Rutgers Law Review. She received her B.A. degree from The Ohio State University.
About the Firm
Buchanan Ingersoll & Rooney PC (www.bipc.com) has more than 450 attorneys and government relations professionals practicing throughout the United States, with offices in California, Delaware, Florida, New Jersey, New York, North Carolina, Pennsylvania, Virginia and Washington, D.C. ###
Contributors
Related Services & Industries
- AFFORDABLE HOUSING AND COMMUNITY DEVELOPMENT
- ANTITRUST & TRADE REGULATION
- APPELLATE
- ATTORNEY UPDATE
- AUTONOMOUS & CONNECTED VEHICLES
- BANKRUPTCY & CREDITORS' RIGHTS
- BLOCKCHAIN & DIGITAL ASSETS
- BUCHANAN IP GUEST ASSOCIATE PROGRAM
- BUCHANAN LABS
- BUSINESS TAX
- CANNABIS
- CLASS ACTIONS
- COAL
- COMBINED HEAT & POWER (CHP)
- COMMERCIAL FINANCE
- CONSTRUCTION
- CONSUMER DEFENSE
- CONSUMER PRODUCTS
- CONTACT INFORMATION
- CONVERGENCE: M&A INSIGHTS IN HEALTHCARE
- COPYRIGHT
- CORONAVIRUS (COVID-19)
- CORPORATE
- CORPORATE COMPLIANCE
- CORPORATE TRANSPARENCY ACT
- CRIMINAL DEFENSE & GOVERNMENT ENFORCEMENT
- CYBERSECURITY & DATA PRIVACY
- DIVERSITY & INCLUSION
- DRUG TARGET ANALYSIS
- E-DISCOVERY
- EDUCATION
- EMERGING COMPANIES
- EMPLOYEE BENEFITS & ERISA
- EMPLOYMENT LITIGATION
- ENERGY
- ENTERTAINMENT, MEDIA & SPORTS
- ENVIRONMENTAL
- ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)
- ESTATES & TRUSTS
- EXECUTIVE COMPENSATION
- FAMILY OFFICE
- FDA & BIOTECHNOLOGY
- FINANCE
- FRANCHISE & DISTRIBUTION
- GOVERNMENT RELATIONS & PUBLIC POLICY
- HEALTHCARE
- HEALTHCARE ADMINISTRATIVE & JUDICIAL PROCEEDINGS
- HEALTHCARE INFORMATION SECURITY & PRIVACY
- HEALTHCARE LITIGATION
- HEALTHCARE REGULATORY & COMPLIANCE
- HEALTHCARE TRANSACTIONS
- HOSPITALITY
- HR & EMPLOYEE RELATIONS ISSUES
- IMMIGRATION
- INNOVATIVE HEALTHCARE DELIVERY & PAYMENT
- INSIDER INSIGHTS: 100 DAYS OF BIDEN
- INSURANCE & REINSURANCE
- INTELLECTUAL PROPERTY
- INTERNAL INVESTIGATIONS
- INTERNATIONAL SERVICES
- INTERNATIONAL TAX
- INTERNATIONAL TRADE & NATIONAL SECURITY
- IP LITIGATION
- LABOR & EMPLOYMENT
- LIFE SCIENCES
- LIFE SCIENCES LITIGATION
- LITIGATION
- MANUFACTURING
- MARITIME & ADMIRALTY
- MATRIMONIAL & FAMILY LAW
- MERGERS & ACQUISITIONS
- NATIONAL SECURITY EXPORT CONTROLS AND ECONOMIC SANCTIONS
- NONPROFIT ORGANIZATIONS
- OIL & GAS
- OPPORTUNITY ZONES
- PASS-THROUGH ENTITIES
- PATENT COUNSELING & STRATEGIC ADVICE
- PATENT OFFICE LITIGATION
- PATENT PROCUREMENT
- POST-ACUTE & LONG-TERM CARE
- POWER GENERATION & UTILITY
- PRIVATE EQUITY AND VENTURE CAPITAL
- PRODUCT LIABILITY
- PUBLIC FINANCE
- PUBLIC PROCUREMENT & BID PROTESTS
- REAL ESTATE
- REAL ESTATE FINANCE
- REAL ESTATE TRANSACTIONS
- REIMBURSEMENT & MANAGED CARE
- RENEWABLES AND ALTERNATIVE ENERGY
- SECURITIES & SEC
- SECURITY ALARM
- SPORTS
- STATE & LOCAL TAX
- TAX
- TAX CONTROVERSY
- TECHNOLOGY, LICENSING AND COMMERCIAL CONTRACTS
- TITLE IX
- TRADE REMEDIES
- TRADE SECRETS & RESTRICTIVE COVENANTS